Appendix 4

SASB Index Table

Code	Accounting Metric	Disclosure	Referenced Chapter	Corresponding SDGs	Page number
Topic: Safety of Clinical Trial Participants					
HC-BP-210a.1	Discussion, by world region, of management process for ensuring quality and patient safety during clinical trials	The risk assessment for clinical trials is performed by a CRO, and the internal standard operating procedure "Vendor Selection and Management" is the main requirement for performing quality assurance and quality management activities in clinical trials. There are no cases of clinical trials discontinued with CROs due to GCP violations. At each stage of clinical development, we have an audit and inspection mechanism and comply with the "Declaration of Helsinki" and the "International Council for the Regulation of Pharmaceuticals Good Clinical Practice (ICH-GCP)." Written informed consent shall be obtained from the subjects before the clinical trials are officially launched, and strictly screening suitable subjects according to the inclusion and exclusion criteria of the investigational new drug (IND) application.	1.3 R&D of innovative biopharmaceuticals		29
HC-BP-210a.2	Number of FDA Sponsor Inspections related to clinical trial management and pharmacovigilance that resulted in: (1) Voluntary Action Indicated (VAI) and (2) Official Action Indicated (OAI)	No such information is available at this time.			
HC-BP-210a.3	Total amount of monetary losses as a result of legal proceedings associated with clinical trials in developing countries	No such information is available at this time.			
Topic: Access to Medicines					
HC-BP-240a.1	Description of actions and initiatives to promote access to health care products for priority diseases and in priority countries as defined by the Access to Medicine Index	One of the Company's 4 focused disease areas is Hematologic diseases. As of the issuance of this report, the drug BESREMi ® for the treatment of PV has been sold in 18 countries in Europe. We are also sponsoring the MPN Asia for 6 consecutive years since 2016 and the American Society of Hematology (ASH) in 2020, so that physicians and scholars around the world who are concerned about MPN disease can continue to have access to the latest research and treatment modalities. The subsections of Chapter 6 of this report describe in detail of our Access to Medicine strategy, implementation plan and annual results, and future goals following the Access to Medicine Index, 2020 framework,.	1.5 Global commercialization blueprint		32 141~158

Code	Accounting Metric	Disclosure	Referenced Chapter	Corresponding SDGs	Page number
HC-BP-240a.2	List of products on the WHO List of Prequalified Medicinal Products as part of its Prequalification of Medicines Programme (PQP)	No such drug is available at this time.			
Topic: Affordability & Pricing					
HC-BP-240b.1	Number of settlements of Abbreviated New Drug Application (ANDA) litigation that involved payments and/or provisions to delay bringing an authorized generic product to market for a defined time period	No such information is available at this time.			
HC-BP-240b.2	Percentage change in: (1) average list price and (2) average net price across U.S. product portfolio compared to previous year	No drugs have been sold in the U.S.			
HC-BP-240b.3	Percentage change in: (1) list price and (2) net price of product with largest increase compared to previous year	At present, the Company's pricing strategy is to formulate reasonable and fair prices based on the affordability of medical expenses in various countries with reference to the "WHO Guideline on Country Pharmaceutical Pricing Policies" issued by the World Health Organization (WHO). In the future, we will continue to track the price of drugs around the world to ensure patient affordability.	6.4 A stable, safe and high-quality drug supply chain		155
Topic: Drug Safety					
HC-BP-250a.1	List of products listed in the Food and Drug Administration's (FDA) MedWatch Safety Alerts for Human Medical Products database	The Company has completed the establishment of a pharmacovigilance mechanism at the headquarter, and the subsidiaries and other drug supplying countries or regions will complete the establishment in accordance with local regulations and drug marketing schedules. We will continue to monitor the safety and risk management of new drugs after they are launched. No drugs have been sold in the U.S., and there have been no adverse drug reaction reports or recalls of drugs sold worldwide.	3.6 Effective pharmacovigilance and recall mechanism		98
HC-BP-250a.2	Number of fatalities associated with products as reported in the FDA Adverse Event Reporting System				
HC-BP-250a.3	Number of recalls issued; total units recalled				
HC-BP-250a.4	Total amount of product accepted for takeback, reuse, or disposal				
HC-BP-250a.5	Number of FDA enforcement actions taken in response to violations of current Good Manufacturing Practalsoices (cGMP), by type				

Code	Accounting Metric	Disclosure	Referenced Chapter	Corresponding SDGs	Page number
Topic: Counterfeit Drugs					
HC-BP-260a.1	Description of methods and technologies used to maintain traceability of products throughout the supply chain and prevent counterfeiting	We have established records of serial number, batch number and factory activities for each batch of pharmaceutical products to ensure batch flow and traceability, and managed and tracked them with standard operating procedures such as the "Product Code and Batch Number Coding Procedures." We have also formulated "Product Secondary Packaging and Serialization Batch Record" to regulate the operation process of commercial packaging and serialization of products by overseas outsourced processing plants. BESREMi®, which is expected to be sold in the US market, has also completed the introduction of drug serialization in 2020.	3.1 Constructing a comprehensive supply chain system 3.6 Effective pharmacovigilance and recall mechanism		76 103
HC-BP-260a.2	Discussion of process for alerting customers and business partners of potential or known risks associated with counterfeit products	When a drug is reported to have a known or probable manufacturing defect, deterioration, counterfeit or any other serious quality problem, our QA department will initiate an investigation and initiate product recall procedures and recovery actions. Furthermore, according to the hazard level of drugs, we remove the drugs from the user-end within a certain period of time, properly dispose of the recovered product, and notify the local competent authority.	3.6 Effective pharmacovigilance and recall mechanism		103
HC-BP-260a.3	Number of actions that led to raids, seizure, arrests, and/or filing of criminal charges related to counterfeit products	No such information is available at this time.			
Topic: Ethical Marketing					
HC-BP-270a.1	Total amount of monetary losses as a result of legal proceedings associated with false marketing claims	No such information is available at this time.			57
HC-BP-270a.2	Description of code of ethics governing promotion of off-label use of products	In terms of marketing and labeling, we strictly follow the ethical standards of the WHO and other countries in the pharmaceutical industry. In order to ensure that our pharmaceutical employees interact with healthcare professionals in a reasonable manner and in accordance with relevant pharmaceutical and medical regulations, we have received internal training and legal education on the ethical standards of pharmaceutical marketing. For more details, please refer to 2.3 Compliance and Business ethics.	2.3 Compliance and business ethics		

Code	Accounting Metric	Disclosure	Referenced Chapter	Corresponding SDGs	Page number
Topic: Employee Recruitment, Developing & Retention					
HC-BP-330a.1	Discussion of talent recruitment and retention efforts for scientists and research and development personnel	The Company creates a stable working environment for retaining talents through compensation and benefits, friendly environment, humane management, smooth internal rotation and training and development. We are recruiting biomedical and R&D talents in various professional fields, and actively recruiting clinical and global management professionals. We have recruited more than 30 new R&D and medical research professionals worldwide in 2020, accounting for 10% of the total workforce.	4.1 A happy workplace		109
HC-BP-330a.2	(1) Voluntary and (2) involuntary turnover rate for: (a) executives/senior managers, (b) midlevel managers, (c) professionals, and (d) all others	The retention rate for executive positions in 2020 was 93.94%, and the growth rate of all PharmaEssentia's employees has continued to grow steadily over the past three years. Please refer to 4.1 A Happy Workplace for details and calculations of our new entry and retention rates.	4.1 A happy workplace		109
Topic: Supply Chain Management					
HC-BP-430a.1	Percentage of (1) entity's facilities and (2) Tier I suppliers' facilities participating in the Rx-360 International Pharmaceutical Supply Chain Consortium audit program or equivalent third-party audit programs for integrity of supply chain and ingredients	Although we do not currently conduct external audits of our upstream supply chain, we have stringent internal procedures to monitor the selection, evaluation and approval of suppliers of raw materials, materials and instruments/equipment. We also conduct supplier/contractor evaluations on a regular basis each year, using a combination of internal evaluation reviews and on-site audits. For 2 consecutive years, 100% of internal assessments and field audits were completed.	3.2 Accountable Supplier Management		85
Topic: Business Ethics					
HC-BP-510a.1	Total amount of monetary losses as a result of legal proceedings associated with corruption and bribery	No such information is available at this time.			
HC-BP-510a.2	Description of code of ethics governing interactions with health care professionals				
Activity Metrics					
HC-BP-000.A	Number of patients treated	As of Q1 2021, BESREMi® is sold in 18 countries in Europe and used by nearly a thousand patients.	1.5 Global commercialization blueprint		32
HC-BP-000.B	Number of drugs (1) in portfolio and (2) in research and development (Phases 1-3)	The Company has initiated international clinical trials and has accumulated more than 19 clinical trials worldwide, benefiting up to 1,500 patients.	1.3 R&D of innovative biopharmaceuticals 6.2 Innovative medicine - solving unmet medical needs		28 150